Access our on-demand webinar.
Amyotrophic Lateral Sclerosis (ALS) is a debilitating neurodegenerative disease with limited treatment options and unmet medical needs. These high patient needs drive significant basic and drug discovery research, which requires relevant preclinical models. This webinar, developed in collaboration with Taconic Biosciences, discusses the impact the SOD1G93A rat model can make in drug discovery for ALS.
Download this webinar to learn more about the development of the SOD1G93A rat model and the motor phenotypes seen in a 16-week longitudinal study and their correlation to clinically relevant biomarkers.
Feature speakers include Dr. Jessica Ramadhin, Field Applications Scientist, from Taconic Biosciences, and Dr. Christopher M. Butt, Senior Director–Neuroscience, from Inotiv.
In this webinar, we:
- Discuss the development of a rat model that expresses human SOD1 with the G93A mutation and why the G93A mutation is relevant to ALS
- Explore the disease phenotype of the SOD1G93A rat model
- Provide insight into how variability in disease phenotype of the SOD1G93A rat model is addressed in study planning
Complete the form to access the on-demand webinar today.
